Restore Mind Medicine

Key Dates MM-120 Strategy Jul 8 2023 Aug 8 2023 Sep 8 2023 Oct 2023 Nov 2023 Dec 2023 Finalize Phase III protocol for MM-120 in GAD. Finalize data entrance and begin analysis of UHB trial data. Begin working on FDA briefing document. This will be a two-dose regimen; a one dose regimen will be in post-market evaluation. Submit FDA meeting request. Begin engagement with Contract-Research-Organization who will manage the Phase III trial. Submit FDA briefing document. Meet with the FDA in early October. After the FDA meeting, MindMed will finalize the protocol, select sites for trial, and submit protocol to the IRB. Start-up activities, including site initiation visits. Dose the first patient. 65

View entire presentation